百蕊颗粒治疗儿童急性上呼吸道感染疗效及安全性系统评价  

Systematic evaluation of the efficacy and safety of Bairui granules in the treatment of acute upper respiratory tract infections in children

作　　者：张小龙[1] 闫孝永 付宏 李静[1] ZHANG Xiaolong;YAN Xiaoyong;FU Hong;LI Jing(Department of Pediatrics,Chongqing University Jiangjin Hospital/Central Hospital of Jiangjin District,Chongqing 402260,China)

机构地区：[1]重庆大学附属江津医院/重庆市江津区中心医院儿科,重庆市402260

出　　处：《临床合理用药杂志》2024年第14期32-36,共5页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的系统评价百蕊颗粒治疗儿童急性上呼吸道感染(AURTI)的疗效及安全性。方法通过计算机系统检索中国知网、万方数据与维普网数据库自建库至2022年9月有关百蕊颗粒治疗儿童AURTI的随机对照研究,并按照Cochrane质量评价标准对纳入研究的方法学质量进行评估,运用RevMan 5.4软件进行Meta分析。结果纳入文献10篇,涉及患儿1257例。Meta分析显示百蕊颗粒组总有效率高于对照组(OR=4.26,95%CI:2.94~6.16,P<0.00001)。依据疾病类型、治疗疗程进行亚组分析,结果显示,疱疹性咽峡炎患者与非疱疹性咽峡炎患者百蕊颗粒组总有效率均高于对照组(OR=5.34,95%CI:3.23~8.84,P<0.00001;OR=3.12,95%CI:1.80~5.42,P<0.0001);疗程3~5 d与6~7 d百蕊颗粒组总有效率均高于对照组(OR=5.24,95%CI:3.20~8.59,P<0.00001;OR=3.14,95%CI:1.79~5.52,P<0.0001)。百蕊颗粒组退热时间、咽喉部症状消退时间短于对照组(MD=-1.23,95%CI:-1.78~-0.68,P<0.0001;MD=-1.38,95%CI:-1.65~-1.11,P<0.00001)。百蕊颗粒组与对照组不良反应总发生率比较差异无统计学意义(OR=2.09,95%CI:0.69~6.33,P=0.19)。结论百蕊颗粒治疗儿童AURTI疗效较好,且不会增加不良反应。Objective To evaluate the efficacy and safety of Bairui granules in the treatment of acute upper respiratory tract infection(AURTI)in children.Methods The randomized controlled trials on the treatment of children′s AURTI with Bairui granules from the establishment of the database to September 2022 were collected in the databases of CNKI,Wanfang and VIP,the methodological quality of the included studies were evaluated by using the Cochrane quality evaluation criteria,RevMan 5.4 software was used for meta analysis.Results A total of 10 studies were included,involving 1257 children.Meta analysis showed that the total effective rate of Bairui granules group was higher than that of control group(OR=4.26,95%CI:2.94~6.16,P<0.00001).Subgroup analysis was conducted based on disease type and treatment course,and the results showed that the total effective rate of the Bairui granules group was higher in both patients with herpetic pharyngitis and non herpetic pharyngitis than in the control group(OR=5.34,95%CI:3.23~8.84,P<0.00001;OR=3.12,95%CI:1.80~5.42,P<0.0001);The total effective rate of the Bairui granules group was higher than that of the control group(OR=5.24,95%CI:3.20~8.59,P<0.00001;OR=3.14,95%CI:1.79~5.52,P<0.0001)after 3~5 days and 6~7 days of treatment.The antipyretic time and throat symptom resolution time of Bairui granules group were shorter than those of control group(MD=-1.23,95%CI:-1.78~-0.68,P<0.0001;MD=-1.38,95%CI:-1.65~-1.11,P<0.00001).There was no statistically significant difference in the total incidence of adverse reactions between Bairui granules group and control group(OR=2.09,95%CI=0.69~6.33,P=0.19).Conclusion Bairui granules has a good therapeutic effect on children with AURTI and does not increase adverse reactions.

关 键 词：急性上呼吸道感染 儿童 百蕊颗粒 系统评价 

分 类 号：R725.6[医药卫生—儿科]